The novel PI3K inhibitor S1 synergizes with sorafenib in non-small cell lung cancer cells involving the Akt-S6 signaling
- 159 Downloads
Non-small cell lung cancer (NSCLC) has been the major cause of cancer-related deaths worldwide. Targeted therapy has been available as an additive strategy for NSCLC patients, but the inevitable resistance to mono-targeted agents has largely hampered its usage in the clinic. We have previously designed and synthesized a novel small molecule compound S1, 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl) benzamides and demonstrated its inhibition of PI3K and mTOR as well as the anti-tumor potential. In the present study, we have identified that S1 alone or combined with the multi-kinase inhibitor sorafenib can inhibit the in vitro cell proliferation of NSCLC cells (A549, NCI-H157 and 95D cells) and tumor growth in the A549 xenograft model. S1 alone produced inhibitory effects on the colony formation, cell migration and invasion and angiogenesis, with more pronounced inhibition when used with sorafenib. We further revealed that S1 mainly inhibited the Akt/S6 phosphorylation while sorafenib mostly decreased the phosphorylation of ERK. Together, the novel PI3K/mTOR inhibitor S1 per se exhibits strong anti-tumor effects in NSCLC cells and A549 xenograft, effects possibly via its inhibition of cell proliferation, invasion and migration and angiogenesis. The combination of S1 and sorafenib exerts potentiated anti-tumor effects, in which the underlying mechanisms may involve their differential modulation of the phosphorylation of Akt and S6 in the PI3K/Akt/mTOR cascades and ERK phosphorylation in the Raf/MEK/ERK pathways. The combination of S1 and sorafenib could be used as an additive approach in treating NSCLC in the clinic.
KeywordsLung cancer Sorafenib S1 Angiogenesis Phosphorylation
This work was supported by a grant from the Shanghai Science and Technology Committee (No.18DZ2290900).
Compliance with ethical standards
Conflict of interest
Juan Wang declares that she has no conflict of interest. Shumei Ma declares that she has no conflict of interest. Xiuhua Chen declares that she has no conflict of interest. Sanqi Zhang declares that he has no conflict of interest. Zhiyong Wang declares that he has no conflict of interest. Qibing Mei declares that he has no conflict of interest.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed.
Informed constent was obtained from all individual participants included in this study.
- 5.J E, Xing J, Gong H, He J, Zhang W (2015) Combine MEK inhibition with PI3K/mTOR inhibition exert inhibitory tumor growth effect on KRAS and PIK3CA mutation CRC xenografts due to reduced expression of VEGF and matrix metallopeptidase-9. Tumor Biol 36(2):1091–1097. https://doi.org/10.1007/s13277-014-2667-5 CrossRefGoogle Scholar
- 11.Maira SM, Stauffer F, Brueggen J, Furet P, Schnell C, Fritsch C, Brachmann S, Chene P, De Pover A, Schoemaker K, Fabbro D, Gabriel D, Simonen M, Murphy L, Finan P, Sellers W, Garcia-Echeverria C (2008) Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity. Mol Cancer Ther 7(7):1851–1863. https://doi.org/10.1158/1535-7163.MCT-08-0017 CrossRefGoogle Scholar
- 12.Knight SD, Adams ND, Burgess JL, Chaudhari AM, Darcy MG, Donatelli CA, Luengo JI, Newlander KA, Parrish CA, Ridgers LH, Sarpong MA, Schmidt SJ, Van Aller GS, Carson JD, Diamond MA, Elkins PA, Gardiner CM, Garver E, Gilbert SA, Gontarek RR, Jackson JR, Kershner KL, Luo L, Raha K, Sherk CS, Sung CM, Sutton D, Tummino PJ, Wegrzyn RJ, Auger KR, Dhanak D (2010) Discovery of GSK2126458, a highly potent inhibitor of PI3K and the mammalian target of rapamycin. ACS Med Chem Lett 1(1):39–43. https://doi.org/10.1021/ml900028r CrossRefGoogle Scholar
- 13.Shao T, Wang J, Chen JG, Wang XM, Li H, Li YP, Li Y, Yang GD, Mei QB, Zhang SQ (2014) Discovery of 2-methoxy-3-phenylsulfonamino-5-(quinazolin-6-yl or quinolin-6-yl)benzamides as novel PI3K inhibitors and anticancer agents by bioisostere. Eur J Med Chem 75:96–105. https://doi.org/10.1016/j.ejmech.2014.01.053 CrossRefGoogle Scholar
- 15.Gridelli C, Maione P, Del Gaizo F, Colantuoni G, Guerriero C, Ferrara C, Nicolella D, Comunale D, De Vita A, Rossi A (2007) Sorafenib and sunitinib in the treatment of advanced non-small cell lung cancer. Oncologist 12(2):191–200. https://doi.org/10.1634/theoncologist.12-2-191 CrossRefGoogle Scholar
- 18.Paz-Ares L, Hirsh V, Zhang L, de Marinis F, Yang JC, Wakelee HA, Seto T, Wu YL, Novello S, Juhasz E, Aren O, Sun Y, Schmelter T, Ong TJ, Pena C, Smit EF, Mok TS (2015) Monotherapy Administration of Sorafenib in patients with non-small cell lung Cancer (MISSION) trial: a phase III, multicenter, placebo-controlled trial of Sorafenib in patients with relapsed or refractory predominantly nonsquamous non-small-cell lung Cancer after 2 or 3 previous treatment regimens. J Thorac Oncol 10(12):1745–1753. https://doi.org/10.1097/JTO.0000000000000693 CrossRefGoogle Scholar
- 19.Kim ES, Herbst RS, Wistuba II, Lee JJ, Blumenschein GR Jr, Tsao A, Stewart DJ, Hicks ME, Erasmus J Jr, Gupta S, Alden CM, Liu S, Tang X, Khuri FR, Tran HT, Johnson BE, Heymach JV, Mao L, Fossella F, Kies MS, Papadimitrakopoulou V, Davis SE, Lippman SM, Hong WK (2011) The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov 1(1):44–53. https://doi.org/10.1158/2159-8274.CD-10-0010 CrossRefGoogle Scholar
- 23.Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, Egia A, Sasaki AT, Thomas G, Kozma SC, Papa A, Nardella C, Cantley LC, Baselga J, Pandolfi PP (2008) Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J Clin Invest 118(9):3065–3074. https://doi.org/10.1172/JCI34739 Google Scholar
- 27.Zhan P, Wang J, Lv XJ, Wang Q, Qiu LX, Lin XQ, Yu LK, Song Y (2009) Prognostic value of vascular endothelial growth factor expression in patients with lung cancer: a systematic review with meta-analysis. J Thorac Oncol 4(9):1094–1103. https://doi.org/10.1097/JTO.0b013e3181a97e31 CrossRefGoogle Scholar
- 28.Newell P, Toffanin S, Villanueva A, Chiang DY, Minguez B, Cabellos L, Savic R, Hoshida Y, Lim KH, Melgar-Lesmes P, Yea S, Peix J, Deniz K, Fiel MI, Thung S, Alsinet C, Tovar V, Mazzaferro V, Bruix J, Roayaie S, Schwartz M, Friedman SL, Llovet JM (2009) Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 51(4):725–733. https://doi.org/10.1016/j.jhep.2009.03.028 CrossRefGoogle Scholar